Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells（Umbilical Cord Derived）
Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Mesenchymal Stem Cells (MSC) is a non Hematopoietic Stem Cells (HSC) in adult bone marrow and
takes part in the bone marrow microenvironment. The response rate of early treatment on
Children's SAA application combined with anti-thymocyte globulin (ATG) (40-50 days after ATG
treatment) is associated with long-term effect. The injection of Umbilical Cord Derived
Mesenchymal Stem Cells combined with ATG improves the efficacy of children with SAA.